Low- and Middle-Income Countries: Enhancing Vaccine Coverage Through Technology

The Power of Evidence: A Comprehensive Analysis (Part1)

1. Rigorous Research Methodology

• Time frame: January 2010 to August 2023.

• Sources: PubMed, EMBASE, Cochrane Library, BMJ Health & Care Informatics.

• Initial collection: 6,535 screened studies.

• Final analysis: 27 studies meeting strict inclusion criteria.

• Total reach: 354,979 children across 17 LMICs.

The Power of Evidence: A Comprehensive Analysis (Part2)

2. Focus on Population and Vaccines

• Primary target: Children up to one year of age—full vaccination coverage by age one and the third pentavalent dose coverage rate.
• Vaccine types: Pentavalent (Diphtheria, Pertussis (whooping cough), Tetanus, Hepatitis B, and Haemophilus influenzae type b (Hib)), measles-containing vaccines, PCV (Pneumococcal Conjugate Vaccine), and polio.
• Geographic scope: Africa (20 studies), Asia (6 studies), and South America (1 study).
• Special emphasis: Under-immunized and zero-dose children.

Digital Interventions: Mapping the Landscape

ICT Solutions Analyzed

• 1. Digital reminders-19 studies. Including:
  a. automatic and manual Short Message System (SMS)
  b. phone calls
   
• 2. Electronic Immunization Registries (EIR)-3 studies. Including:
  a. Data management
  b. Coverage monitoring
  c. Real-time tracking
   
• 3. Software tools-(3 studies). Including:
  a. Twilio cloud communications platform integration.
  b. Automated text and voice calling system.
  c. Web-based reminder platform
   
• 4. Supply Chain Management Tools (3 studies):
  a. Stock monitoring
  b. Cold chain management
  c. Resource allocation

CIMA Care's Distinctive Achievement

CIMA Care's Distinctive Achievement

Among the reviewed interventions, CIMA Care stands out as the only solution specifically examined for vaccination return rates. Our innovative app demonstrated:

• Increased return rates for follow-up vaccinations.
• Improved timeliness of vaccination schedules.
• Enhanced parent engagement and empowerment.
• Reduction in the default rate.

Key Effectiveness Metrics

The meta-analysis of ICT impact revealed significant improvements:

• Full immunization by age one (OR 2.61, 95% CI 1.20-5.67). This displays that children were 2.61 times more likely to get all their vaccines by their first birthday, and we can be 95% confident that they were between 1.2 and 5.67 times more likely to complete their vaccinations.

• Pentavalent vaccine third dose coverage (OR 2.32, 95% CI 1.34-4.03). This means that children were 2.32 times more likely to get their third pentavalent shot, and we can be 95% confident that they were between 1.34 and 4.03 times more likely to get this important vaccine dose.

• CIMA Care's specific contribution to return rates showed a 19% relative risk reduction. This indicates that for every 100 children in the vaccination program, approximately 19 fewer would be expected to have late appointments when using CIMA compared to standard care, an important improvement in vaccination timeliness achieved through the CIMA intervention.

Implications of Digital Solutions for Global Health

The review confirms the vital role of digital solutions in strengthening immunization programs, with particular success in:

• Improving vaccination coverage.
• Enhancing data accuracy.
• Strengthening supply chain management.
• Facilitating better parent engagement.

CIMA Care: Pioneering the Future

As validated by this valuable systematic review, CIMA Care continues to conduct innovation in digital immunization solutions. Our commitment to improving global vaccination rates through technology remains reliable, with proven results in:

• Automated reminder systems.

• User-friendly interfaces.

• Real-time tracking capabilities.

• Evidence-based health messaging.

Join us in transforming global health through digital innovation. Learn more about how CIMA Care is shaping the future of immunization at
www.cima.care.

Enjoyed this article?

Share it with your friends on LinkedIn:   Leveraging Technology for Better Immunization: Insights from the Latest Lancet Study 
Follow us on LinkedIn for more updates and insights: Cima Care GmbH